An activity‐based bioprobe differentiates a novel small molecule inhibitor from a LOXL2 antibody and provides renewed promise for anti‐fibrotic therapeutic strategies.
Saved in:
| Title: | An activity‐based bioprobe differentiates a novel small molecule inhibitor from a LOXL2 antibody and provides renewed promise for anti‐fibrotic therapeutic strategies. |
|---|---|
| Authors: | Findlay, Alison1 (AUTHOR), Turner, Craig1 (AUTHOR), Schilter, Heidi1 (AUTHOR), Deodhar, Mandar1 (AUTHOR), Zhou, Wenbin1 (AUTHOR), Perryman, Lara1 (AUTHOR), Foot, Jonathan1 (AUTHOR), Zahoor, Amna1 (AUTHOR), Yao, Yimin1 (AUTHOR), Hamilton, Ross1 (AUTHOR), Brock, Mary2 (AUTHOR), Raso, Christina2 (AUTHOR), Stolp, Jessica1 (AUTHOR), Galati, Marie1 (AUTHOR), Hamprecht, Dieter1 (AUTHOR), Charlton, Brett1 (AUTHOR), Jarolimek, Wolfgang1 (AUTHOR) Wolfgang.jarolimek@pharmaxis.com.au |
| Source: | Clinical & Translational Medicine. Nov2021, Vol. 11 Issue 11, p1-5. 5p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 20011326 |
|---|---|
| DOI: | 10.1002/ctm2.572 |
